drugset / Trial / NCT02127684

Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing

NCT02127684

Phase 2 Withdrawn Maturi, Raj K., M.D., P.C.
RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators would like to investigate the efficacy of more frequent treatment with Lucentis for subjects with persistent diabetic macular edema despite standard dosing regimen.

Timeline

Start
Primary completion
2015-08
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.3 mg Intravitreal